Angiotensin Converting Enzyme Inhibitor Enalapril in the Treatment of Endomyocardial Fibrosis in Patients with Lymphogranulomatosis Subjected to Radio- and Chemotherapy

Kardiologiya

Volumn 42, Issue 11, 2002, Pages 48-51

  Loseva, M I ^a   Purtova, L A ^a   Gavalova, R F ^a  

^a NONE

Author keywords

Enalapril; Endomyocardial fibrosis; Lymphogranulomatosis; Metabolic therapy

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL;

ADOLESCENT; ADULT; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; FEMALE; HEART MUSCLE FIBROSIS; HODGKIN DISEASE; HUMAN; MALE; MIDDLE AGED; RADIOTHERAPY;

ADOLESCENT; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ENALAPRIL; ENDOMYOCARDIAL FIBROSIS; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; RADIOTHERAPY;

EID: 0347934634     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Sutton M.S.J., Pfeffer M.A., Plappert T. et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction: the protective effects of captopril. Circulation 1994;89:68-75.
2. Grinberg B., Quinones M.A., Koilpillai C. et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular disfunction: results for the SOLVD echocardiography sydstudy. Circulation 1995;91:2573-2581.
3. Tamargo J., Delpon E., Valenzuela C. Treatment of left ventricular hypertrophy in hypertensive patients. Eur Heart J 1993;14:102-106.